Join Ads Marketplace to earn through podcast sponsorships.
Manage your ads with dynamic ad insertion capability.
Monetize with Apple Podcasts Subscriptions via Podbean.
Earn rewards and recurring income from Fan Club membership.
Get the answers and support you need.
Resources and guides to launch, grow, and monetize podcast.
Stay updated with the latest podcasting tips and trends.
Check out our newest and recently released features!
Podcast interviews, best practices, and helpful tips.
The step-by-step guide to start your own podcast.
Create the best live podcast and engage your audience.
Tips on making the decision to monetize your podcast.
The best ways to get more eyes and ears on your podcast.
Everything you need to know about podcast advertising.
The ultimate guide to recording a podcast on your phone.
Steps to set up and use group recording in the Podbean app.
Join Ads Marketplace to earn through podcast sponsorships.
Manage your ads with dynamic ad insertion capability.
Monetize with Apple Podcasts Subscriptions via Podbean.
Earn rewards and recurring income from Fan Club membership.
Get the answers and support you need.
Resources and guides to launch, grow, and monetize podcast.
Stay updated with the latest podcasting tips and trends.
Check out our newest and recently released features!
Podcast interviews, best practices, and helpful tips.
The step-by-step guide to start your own podcast.
Create the best live podcast and engage your audience.
Tips on making the decision to monetize your podcast.
The best ways to get more eyes and ears on your podcast.
Everything you need to know about podcast advertising.
The ultimate guide to recording a podcast on your phone.
Steps to set up and use group recording in the Podbean app.
Randy Baron, one of the most popular YAVP guests, returns to discuss his investment thesis on Renalytix (RNLX). Randy sees similarities between RNLX and EXAS, which was a controversial stock that has rocketed over the last few years as the company's diagnostic product gained momentum. While not without risk, Randy thinks RNLX could be even bigger if successful as they are attacking the much larger Chronic Kidney Disease (CKD) market, and he discusses all of the signs he sees that the company is about to inflect.
Randy's first appearance on Amyris (AMRS): https://www.youtube.com/watch?v=zCKxUHfCoQQ&t=1s
Chapters
0:00 Intro
1:20 RNLX overview
8:55 Where does RNLX fall into CKD?
14:00 Why now is the time for RNLX in CKD
20:40 How RNLX can operate even without MICT
24:30 More on RNLX and Medicare
25:30 When will RNLX get FDA approval?
33:40 What if RNLX doesn't get FDA approval?
37:30 RNLX's CEO and founder, James McCullough
43:40 Why is RNLX so under the radar?
46:40 Comping RNLX to Theranos
50:00 Randy's closing thoughts
Ave Maria Focused Fund's Chadd Garcia talks eDreams, travel subscription platform in Europe $EDR.MC
Chris DeMuth's State of the Markets August 2023
Firstlight Management's AJ Secrist provides update on $LW thesis post-earnings and pre-Investor Day
Choice Equities' Mitchell Scott making the case that $CROX is not a fad
Hedgeye's Daniel Biolsi on state of the Consumer Staples sector + $COST $ACI $KVUE $HSY $IFF
Focus Capital's Mordechai Yavneh returns to explain how $SIMO / $MXL deal fell apart
Ross Levin on Cooperative Investment Certificates (CCIs) issued by Credit Agricole Group
Half Moon Capital's Eric DeLamarter and Brandon Carnovale thesis on Keurig Dr Pepper $KDP
Buckley Capital Partners' Zack Buckley provides update on $XPOF thesis following short report
Chris DeMuth's State of the Markets July 2023
Daniel Payne from ICBLA on $COIN v. SEC (sponsored by Stream by AlphaSense)
Bireme Capital's Evan Tindell on growth tailwinds for African Telecom - Airtel Africa $AAF.L
Cove Street Capital's Jeff Bronchick and Andrew Leaf talk $ECVT Ecovyst + $VSAT Update
Warden Capital's Hawkins Entrekin on $VNO and debunking New York City commercial real estate market
Colarion Partners' Sam Haskell on the financial sector and banks
Raper Capital's Jeremy Raper outlines strategic alternatives for Alto Ingredients $ALTO
Chris DeMuth's State of the Markets June 2023
Papyrus Capital's Nitin Sacheti updates his $VATE thesis
Creek Drive Capital's Kevin Mak on why $PGY has been largely ignored by the AI hoopla
Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech
Create your
podcast in
minutes
It is Free
The Minority Mindset Show
U.S Property Podcast
Dubai Property Podcast
The Ramsey Show
The Clark Howard Podcast